RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway
Theranostics · 16.08.2025 · 15 (17) · 9261-9278
DOI: 10.7150/thno.112753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, erschienen am 16.08.2025. Verfasst von Zhuo Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Sout…. Hauptthemen laut MEDLINE: RNA, Circular, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Neural Cell Adhesion Molecule L1. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China.
Zitieren
APA
Wu, Z., Fang, Z., Zeng, L., Zhang, D., Zhou, Y., & Chen, R. (2025). RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway. Theranostics, 15(17), 9261-9278. https://doi.org/10.7150/thno.112753
Vancouver
Wu Z, Fang Z, Zeng L, Zhang D, Zhou Y, Chen R. RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway. Theranostics. 2025;15(17):9261-9278. doi:10.7150/thno.112753
BibTeX
@article{Wu2025,
author = {Wu, Zhuo and Fang, Zhou and Zeng, Liangtang and Zhang, Dingwen and Zhou, Yu and Chen, Rufu},
title = {RBMS1-mediates the biogenesis of circNFIB promotes perineural invasion of pancreatic ductal adenocarcinoma via the L1CAM/MAPK pathway},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {17},
pages = {9261--9278},
doi = {10.7150/thno.112753}
}
EUVIMED